Barouyr Baroudjian

2.3k total citations
71 papers, 1.1k citations indexed

About

Barouyr Baroudjian is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Barouyr Baroudjian has authored 71 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 26 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in Barouyr Baroudjian's work include Cancer Immunotherapy and Biomarkers (27 papers), Melanoma and MAPK Pathways (23 papers) and Cutaneous Melanoma Detection and Management (13 papers). Barouyr Baroudjian is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Melanoma and MAPK Pathways (23 papers) and Cutaneous Melanoma Detection and Management (13 papers). Barouyr Baroudjian collaborates with scholars based in France, United States and Switzerland. Barouyr Baroudjian's co-authors include Célèste Lebbé, Cécile Pagès, M. Bagot, Julie Delyon, Maxime Battistella, Laëtitia Vercellino, Laetitia Da Meda, Nicole Basset‐Séguin, Jean-Paul Fontaine and Marie-Léa Gauci and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Barouyr Baroudjian

60 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barouyr Baroudjian France 17 624 225 180 170 158 71 1.1k
Martina Kleber Germany 15 527 0.8× 330 1.5× 78 0.4× 117 0.7× 45 0.3× 48 1.1k
M. García García Spain 19 202 0.3× 174 0.8× 123 0.7× 92 0.5× 46 0.3× 73 989
Cornelis M. van Tilburg Germany 14 220 0.4× 122 0.5× 100 0.6× 196 1.2× 95 0.6× 48 802
James Java United States 19 341 0.5× 179 0.8× 262 1.5× 240 1.4× 30 0.2× 56 1.7k
Andrew Owen United Kingdom 14 273 0.4× 90 0.4× 94 0.5× 62 0.4× 27 0.2× 32 765
Thomas J. Hugh Australia 25 900 1.4× 281 1.2× 181 1.0× 539 3.2× 22 0.1× 135 1.9k
Wim Terpstra Netherlands 18 276 0.4× 317 1.4× 47 0.3× 57 0.3× 43 0.3× 36 1.0k
Oliver Teuffel Canada 16 301 0.5× 128 0.6× 133 0.7× 34 0.2× 19 0.1× 30 806
Carmen Ţereanu Italy 10 288 0.5× 197 0.9× 54 0.3× 63 0.4× 61 0.4× 16 1.0k
Susan J. Neuhaus Australia 23 655 1.0× 150 0.7× 65 0.4× 852 5.0× 28 0.2× 77 1.6k

Countries citing papers authored by Barouyr Baroudjian

Since Specialization
Citations

This map shows the geographic impact of Barouyr Baroudjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barouyr Baroudjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barouyr Baroudjian more than expected).

Fields of papers citing papers by Barouyr Baroudjian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barouyr Baroudjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barouyr Baroudjian. The network helps show where Barouyr Baroudjian may publish in the future.

Co-authorship network of co-authors of Barouyr Baroudjian

This figure shows the co-authorship network connecting the top 25 collaborators of Barouyr Baroudjian. A scholar is included among the top collaborators of Barouyr Baroudjian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barouyr Baroudjian. Barouyr Baroudjian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goldwirt, Lauriane, Fanélie Jouenne, N. Kramkimel, et al.. (2024). Continuous intrathecal infusion of nivolumab in advanced melanoma with leptomeningeal disease.. Journal of Clinical Oncology. 42(16_suppl). 9522–9522.
2.
Robert, Caroline, Caroline Dutriaux, Felix Boakye Oppong, et al.. (2024). Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).. Journal of Clinical Oncology. 42(17_suppl). LBA9503–LBA9503. 3 indexed citations
3.
Louveau, Baptiste, Fanélie Jouenne, Barouyr Baroudjian, et al.. (2024). Skin adnexal carcinomas DNA genomic profiling uncovers oncogenic pathways and potential therapeutic targets. SHILAP Revista de lepidopterología. 2. 100206–100206. 1 indexed citations
4.
Goronflot, Thomas, Caroline Dutriaux, Antoine Deleuze, et al.. (2024). Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study. Acta Dermato Venereologica. 104. adv41297–adv41297. 5 indexed citations
5.
Walter‐Petrich, Anouk, N. Dupin, J. Chanal, et al.. (2024). Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicentre retrospective study of 110 patients. British Journal of Dermatology. 190(5). 771–773. 2 indexed citations
6.
Baldini, Capucine, E. Maubec, Christine Longvert, et al.. (2023). Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients. Cancers. 15(17). 4330–4330. 3 indexed citations
7.
Peyrony, Olivier, et al.. (2023). Toxicités immuno-induites chez les patients avec cancer sous immunothérapie par inhibiteurs des checkpoints. Ce que l’urgentiste doit savoir. Annales françaises de médecine d’urgence. 13(4). 241–253.
8.
Cuzzubbo, Stefania, et al.. (2023). P06.17.A OPTIC NEUROPATHY RELATED TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES. Neuro-Oncology. 25(Supplement_2). ii49–ii49.
9.
Robert, Caroline, Célèste Lebbé, Thierry Lesimple, et al.. (2022). Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1. Clinical Cancer Research. 29(5). 858–865. 15 indexed citations
10.
Herms, F., Barouyr Baroudjian, Julie Delyon, et al.. (2022). Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study. Acta Dermato Venereologica. 102. adv00740–adv00740. 12 indexed citations
11.
Goldwirt, Lauriane, Baptiste Louveau, Barouyr Baroudjian, et al.. (2021). Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study. Cancer Chemotherapy and Pharmacology. 88(3). 427–437. 6 indexed citations
12.
Oulès, Bénédicte, Samia Mourah, Barouyr Baroudjian, et al.. (2021). Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 480(2). 475–480. 6 indexed citations
13.
Battistella, Maxime, Julie Delyon, Jean‐Marc Gornet, et al.. (2020). Une complication digestive rare sous anti-PD-1 (pembrolizumab). Annales de Pathologie. 40(4). 320–323. 3 indexed citations
14.
Vercellino, Laëtitia, et al.. (2020). Rôle de la TEP FDG dans l’évaluation de l’extension locorégionale et à distance du mélanome. Médecine Nucléaire. 44(5-6). 305–312.
15.
Baroudjian, Barouyr, et al.. (2018). Avancées thérapeutiques récentes dans la prise en charge du carcinome à cellules de Merkel. Bulletin du Cancer. 106(1). 64–72. 5 indexed citations
16.
Gauci, Marie-Léa, Barouyr Baroudjian, Pauline Laly, et al.. (2017). Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. Seminars in Arthritis and Rheumatism. 47(2). 281–287. 34 indexed citations
17.
Gauci, Marie-Léa, Pauline Laly, Tiphaine Vidal-Trécan, et al.. (2017). Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunology Immunotherapy. 66(11). 1399–1410. 101 indexed citations
18.
Gauci, Marie-Léa, Pauline Laly, Barouyr Baroudjian, et al.. (2016). Diabète de type 1 (DT1) révélé par une acidocétose sous anti-PD1. Annales de Dermatologie et de Vénéréologie. 143(12). S365–S365.
19.
Baroudjian, Barouyr, Maxime Battistella, J. Roux, et al.. (2016). Efficacité du pazopanib dans le dermato-fibrosarcome métastatique résistant à l’imatinib. Annales de Dermatologie et de Vénéréologie. 143(12). S403–S403. 1 indexed citations
20.
Baroudjian, Barouyr, Lise Boussemart, Émilie Routier, et al.. (2014). Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. European Journal of Dermatology. 24(2). 265–267. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martina Kleber Breakdown of academic impact, for papers by M. García García Breakdown of academic impact, for papers by Cornelis M. van Tilburg Breakdown of academic impact, for papers by James Java Breakdown of academic impact, for papers by Andrew Owen Breakdown of academic impact, for papers by Thomas J. Hugh Breakdown of academic impact, for papers by Wim Terpstra Breakdown of academic impact, for papers by Oliver Teuffel Breakdown of academic impact, for papers by Carmen Ţereanu Breakdown of academic impact, for papers by Susan J. Neuhaus
Rankless by CCL
2026